From Zacks Research: The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining approximately 16% year-to-date.
From Zacks Research: The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining approximately 16% year-to-date.